At the recent Heart Rhythm 2019 meeting, we spoke with Dr Douglas Packer (Cardiac Electrophysiologist, Cardiologist and Internist, Mayo Clinic Hospital, Saint Mary’s Campus, Rochester, MN, USA) about the CABANA trial and the limitations of current drug therapy for atrial fibrillation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Douglas Packer has provided consulting services for Abbott, Biosense Webster Inc., Biotronik, Boston Scientific, CardioFocus, Johnson & Johnson, MediaSphere Medical, LLC, Medtronic, St Jude Medical, Siemens, SigNum Preemptive Healthcare, Inc., Spectrum Dynamics and Thermedical. He receives research funding from Abbott, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic, NIH, Roberston Foundation, St Jude Medical, Siemens and Thermedical. He has financial interests in mapping technology through St Jude Medical and Mayo Clinic, has equity in External Beam Ablation Medical Devices and receives royalties from Wiley & Sons, Oxford and St Jude Medical.
1. What are the limitations of current drug therapy for atrial fibrillation? (0:09)
2. What was the rationale behind the Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) trial? (0:58)
3. What were the outcomes of the CABANA trial? (1:39)
4. What were the limitations of the study? (5:04)
5. What impact do you think the results will have on the management of atrial fibrillation? (6:01)
6. What do you have planned for the future? (7:53)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
Share this Video
Related Videos In Atrial Fibrillation
Ole De Backer, TCT 2022: FEops HEARTguide™ Computational Modelling for left atrial appendage (LAA) closure, the PREDICT LAA trial
The PREDICT LAA trial aimed to examine whether cardiac computed tomography- based FEops HEARTguide™ computational modelling would benefit clinical outcomes when planning for left atrial appendage (LAA) closure. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss the PREDICT LAA trial and the next steps. […]
Ole De Backer, TCT 2022: The use of cardiac computed tomography-based patient-specific computational simulations in left atrial appendage (LAA) closure
When performing percutaneous left atrial appendage (LAA) closure, challenges arise that impact clinical outcomes and cardiac computed tomography (CCT)- based patient-specific computational simulations provide device-host interactions. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss these challenges and the use of cardiac computed tomography (CCT)- […]
Hugh Calkins: What can we look forward to at the Heart Rhythm Congress 2022
Prof Hugh Calkins (The Johns Hopkins University School of Medicine, Baltimore, Md, USA) explains how the Arrhythmia Alliance has been instrumental in empowering patients to become advocates for themselves, ask more questions and increase their knowledge. The Heart Rhythm Congress 2022 is back in person and a unique chance to bring patients and healthcare professionals […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!